Heterogeneity of KRAS Mutation Status in Rectal Cancer.
Anti-EGFR targeted therapy is of increasing importance in advanced colorectal cancer and prior KRAS mutation testing is mandatory for therapy. However, at which occasions this should be performed is still under debate. We aimed to assess in patients with locally advanced rectal cancer whether there...
Збережено в:
| Автори: | , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Public Library of Science (PLoS)
2016-01-01
|
| Серія: | PLoS ONE |
| Онлайн доступ: | http://europepmc.org/articles/PMC4827807?pdf=render |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|